Advertisement
Screener

GREENLAND MINES LTD (GRML) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

GREENLAND MINES LTD Share-based Payment Arrangement, Expense

GREENLAND MINES LTD (GRML) reported Share-based Payment Arrangement, Expense of $111.08 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-17

  • GREENLAND MINES LTD share-based payment arrangement, expense for the quarter ending 2026-06-30 was $111.08K, a 71.53% decline year-over-year.
  • GREENLAND MINES LTD share-based payment arrangement, expense for the quarter ending 2026-03-31 was $5.11M, a 161.54% increase year-over-year.
  • GREENLAND MINES LTD share-based payment arrangement, expense for the quarter ending 2025-12-31 was $39.93K, a 93.94% decline year-over-year.
  • GREENLAND MINES LTD share-based payment arrangement, expense for the quarter ending 2025-09-30 was $639.59K, a 67.25% decline year-over-year.
  • GREENLAND MINES LTD share-based payment arrangement, expense for fiscal 2025 was $1.57M, a 40.93% decline from fiscal 2024.
  • GREENLAND MINES LTD share-based payment arrangement, expense for fiscal 2024 was $2.65M.
  • GREENLAND MINES LTD share-based payment arrangement, expense for fiscal 2023 was $0.00.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 3 month as first filedShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 month
2026-06-30$111.08K
10-Q · filed 2026-08-17
$10.56K
10-Q · filed 2026-08-17
$5.26M
derived: sum of 3 quarters · filed 2026-08-17
$5.90M
derived: sum of 4 quarters · filed 2026-08-17
2026-03-31$5.11M
10-Q/A · filed 2026-08-14
$5.15M
derived: sum of 2 quarters · filed 2026-08-14
$5.79M
derived: sum of 3 quarters · filed 2026-08-14
$6.18M
derived: sum of 4 quarters · filed 2026-08-17
2025-12-31$39.93K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14
$679.52K
derived: sum of 2 quarters · filed 2026-08-14
$1.07M
derived: sum of 3 quarters · filed 2026-08-17
$1.57M
10-K/A · filed 2026-08-14
2025-09-30$639.59K
10-Q · filed 2025-11-13
$1.03M
derived: sum of 2 quarters · filed 2026-08-17
$1.53M
10-Q · filed 2025-11-13
$3.64M
derived: sum of 4 quarters · filed 2026-08-17
2025-06-30$390.19K
10-Q · filed 2026-08-17
$885.70K
10-Q · filed 2026-08-17
$3.00M
derived: sum of 3 quarters · filed 2026-08-17
$4.96M
derived: sum of 4 quarters · filed 2026-08-17
2025-03-31$1.95M
10-Q/A · filed 2026-08-14
$495.50K
10-Q · filed 2025-05-15
$2.61M
derived: sum of 2 quarters · filed 2026-08-14
$4.56M
derived: sum of 3 quarters · filed 2026-08-14
$4.60M
derived: sum of 4 quarters · filed 2026-08-14
2024-12-31$659.21K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14
$2.61M
derived: sum of 2 quarters · filed 2026-08-14
$2.65M
derived: sum of 3 quarters · filed 2026-08-14
$2.65M
10-K/A · filed 2026-08-14
2024-09-30$1.95M
10-Q · filed 2025-11-13
$1.95M
10-Q · filed 2024-11-19
$1.99M
derived: sum of 2 quarters · filed 2025-11-13
$1.99M
10-Q · filed 2025-11-13
$2.17M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$37.51K
10-Q · filed 2025-08-18
$37.51K
10-Q · filed 2025-08-18
$215.76K
derived: sum of 3 quarters · filed 2025-08-18
$315.76K
derived: sum of 4 quarters · filed 2025-08-18
2024-03-31$278.25K
10-Q · filed 2025-05-15
$178.25K
derived: sum of 2 quarters · filed 2025-05-15
$278.25K
derived: sum of 3 quarters · filed 2025-05-15
2023-12-31-$100.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$0.00
derived: sum of 2 quarters · filed 2025-03-31
$0.00
10-K · filed 2025-03-31
2023-09-30$100.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19
$100.00K
10-Q · filed 2024-11-19
2023-06-30$0.00
10-Q · filed 2024-08-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43